Cardiol Therapeutics Inc. (CRDL.TO)
| Previous Close | 0.9700 |
| Open | 0.9800 |
| Bid | 0.9300 x 0 |
| Ask | 0.9400 x 0 |
| Day's Range | 0.9300 - 0.9800 |
| 52 Week Range | 0.6500 - 2.6000 |
| Volume | |
| Avg. Volume | 101,341 |
| Market Cap | 60.518M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6330 |
| Earnings Date | Mar 21, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- News Direct
Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis
Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients wit...
- Newsfile
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot
- Baystreet
Stocks in play: Cardiol Therapeutics Inc
Announces the initiation of a Phase II open-label pilot study (NCT05494788), to investigate the tolerance, ...
